Recently, the Guizhou Provincial Public Resources Trading Network issued the "Notice on Canceling the Qualification of the Fourth Batch of 107 Drugs in 2022", and the 107 drugs withdrawn from the network are all actively applied for withdrawal by pharmaceutical companies, including many Shuanghuanglian oral liquid, cold spirit capsules, athlete oral digestion, Banlan root granules and other proprietary Chinese medicine products
.
According to the regulations, after the withdrawal of the network, the above-mentioned enterprises with the same product specification will not be allowed to participate in the drug network in Guizhou Province
for two years.
Industry analysis pointed out that under the background of normalization of collection and procurement, the reasons for the active withdrawal of proprietary Chinese medicine products are generally related to factors such as the increase in raw material prices and the rise in production costs, which means that there is no market in the hospital, and only the choice of withdrawal is available; For enterprises that have not yet been included in the collection, some will choose to actively abandon the hospital and turn to the outside of the hospital to find retail channels
with independent pricing power.
In addition, there are also some pharmaceutical companies that choose to withdraw the network
because of insufficient production capacity.
In addition to Guizhou Province, since the beginning of this year, Gansu, Anhui, Shanxi and other places have issued documents canceling the qualification of drugs hanging on the network, including a large number of proprietary Chinese medicine products
.
For example, in the same August, the Gansu Provincial Public Resources Trading Center issued a notice of application for the withdrawal of hanging net drugs, and a total of 42 online drugs in this batch applied for the withdrawal of waste, including many common proprietary Chinese medicines
such as Angong Niuhuang Pill, Eryi Pill, Liuwei Dihuang Pill Granule, Jiuwei Qianghuo Granule and so on.
These drugs are mainly due to the transformation of production lines, rising costs, shortage of raw materials, suspension of production and other reasons to submit applications for dismantling, can not ensure the normal supply of medical institutions
in Gansu Province.
It is worth mentioning that pharmaceutical companies that apply for dismantling after winning/hanging up the net may face serious consequences
.
According to the "Gansu Provincial Measures for the Integrity Management of Centralized Drug Procurement", in view of the situation of application for dismantling after winning the selection/hanging up the network, the relevant enterprises are treated in good faith, not only the relevant pharmaceutical companies may be recorded with bad records, but at the same time, they will not be allowed to declare
again within the corresponding time.
For example, on June 15, the Hubei Provincial Medical Insurance Bureau issued the "Notice on Publicizing the First Batch of Interprovincial Alliances of Proprietary Chinese Medicines centralized procurement of non-selected varieties of hanging net prices and medical insurance payment standards and other related information", this time the province has a total of 227 proprietary Chinese medicines will be suspended from the net, of which 49 drugs are injectable varieties, these injections were originally a large number of terminals in hospitals, and the industry said that it was difficult to develop
outside the hospital after abandoning the hospital market.
It can be seen from the actions of pharmaceutical companies in various places to withdraw from the network that the survival of proprietary Chinese medicine enterprises is being challenged and facing greater
pressure.
More in the industry, it is believed that a series of actions by these pharmaceutical companies are to avoid the upcoming collection of proprietary Chinese medicines
.
At present, the collection and collection of proprietary Chinese medicines has been launched in Beijing, Hubei, Guangdong, Shandong, Guizhou, Gansu, Anhui, Ningxia and other places, among which the representative Hubei and Guangdong proprietary Chinese medicine alliances have selected the results of the collection and collection of proprietary Chinese medicines, showing that the overall price reduction of proprietary Chinese medicines is around 50%, which is relatively mild
compared with the collection of chemical medicines.
In the first half of this year, the National Medical Insurance Bureau made a unified deployment and coordination of local alliance collection, clarifying that by the end of 2022, the number of drug varieties collected by each province (including the inter-provincial alliance) is not less than 100, and it must contain chemical drugs, proprietary Chinese medicines, orthopedic trauma, oral implants, drug balloons and other consumables
.
The industry believes that the collection of proprietary Chinese medicines is the trend, the future scope or continue to expand, with the living space of proprietary Chinese medicine enterprises continues to decrease, proprietary Chinese medicine enterprises urgently need to be transformed and upgraded, otherwise there may be a large number of small and medium-sized enterprises eliminated
.
